BioTime to Webcast Presentation at the Ladenburg Thalmann 2016 Healthcare Conference
ALAMEDA, Calif.--(BUSINESS WIRE)--Sep. 23, 2016--
BioTime, Inc. (NYSE MKT:BTX), a clinical stage regenerative medicine
company with a focus on pluripotent stem cell technology, today
announced that it will be presenting at the Ladenburg Thalmann
2016 Healthcare Conference in New York City on Tuesday, September 27,
2016, at 1:00 p.m. Eastern Time / 10:00 a.m. Pacific Time.
The Ladenburg Thalmann Healthcare Conference is a well-respected event
for investors who are specifically focused on healthcare and life
sciences companies such as BioTime. This venue allows BioTime’s
management to provide a corporate overview and update on its product
Attendance is by invitation only. However, the presentation will be
webcast live and will also be available for replay at the “Events &
Presentations” page of the “Investors & Media” section on BioTime’s
website at http://www.biotimeinc.com/.
BioTime, Inc. is a clinical-stage biotechnology company focused on
developing and commercializing novel therapies developed from what we
believe to be the world’s premier collection of pluripotent cell assets.
The foundation of our core therapeutic technology platform is
pluripotent cells that are capable of becoming any of the cell types in
the human body. Pluripotent cells have potential application in many
areas of medicine with large unmet patient needs, including various
age-related degenerative diseases and degenerative conditions for which
there presently are no cures. Unlike pharmaceuticals that require a
molecular target, therapeutic strategies based on the use of pluripotent
cells are generally aimed at regenerating or replacing affected cells
and tissues, and therefore may have broader applicability than
In addition to the development of therapeutics, BioTime’s research and
other activities have resulted, over time, in the creation of other
subsidiaries that address other non-therapeutic market opportunities
such as cancer diagnostics, drug development and cell research products,
and mobile health software applications.
BioTime common stock is traded on the NYSE MKT and TASE under the symbol
BTX. For more information, please visit www.biotimeinc.com
or connect with the company on Twitter,
To receive ongoing BioTime corporate communications, please click on the
following link to join our email alert list: http://news.biotimeinc.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160923005182/en/
Source: BioTime, Inc.
Dan L. Lawrence, 510-775-0510
EVC Group, Inc.
Michael Polyviou, 646-445-4800
Gotham Communications, LLC
Bill Douglass, 646-504-0890